OncoMatch/Clinical Trials/NCT05833893
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Is NCT05833893 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies XPO1 inhibitor for nk/t-cell lymphoma.
Treatment: XPO1 inhibitor — Patients with newly diagnosed, pathologically confirmed NK/T-cell lymphoma of stage III-IV treated with XCOPL regimen. 3 weeks for a cycle, with a total of 6-8 cycles.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: allogeneic hematopoietic cell transplant
Lab requirements
Blood counts
WBC ≥ 3.5 x 10^9/L, PLT ≥ 75 x 10^9/L, Hb ≥ 80 g/L
Kidney function
CCr ≥ 60 mL/min
Liver function
AST and ALT ≤ 3.0 ULN; TBIL ≤ 2.0 mg/dL
Normal major organ function, meeting the following definitions: Hematology: WBC ≥ 3.5 x 10 9/L, PLT ≥ 75 x 10 9/L, Hb ≥ 80 g/L; Liver and kidney function: AST and ALT ≤ 3.0 ULN; TBIL ≤ 2.0 mg/dL; CCr ≥ 60 mL/min; liver and kidney function impairment caused by tumor compression is not limited by this; Fibrinogen: normal at first cycle
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05833893 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages